Information Library

Results for: Enrollment & retention - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Energizing Enrollment

    Case Study — October 4, 2011
    The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned.

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Malaria Prevention in Sub-Saharan Africa

    Case Study — June 24, 2011
    This study enabled us to be involved in bringing a malaria vaccine to Africa which could substantially reduce an infant mortality rate that currently stands

  • KoNECT & Quintiles Partner to Advance Clinical Research

    Press Release — May 30, 2011 – The Korea National Enterprise for Clinical Trials (KoNECT) and Quintiles have partnered to produce educational events in South Korea for investigators and biopharmaceutical companies.

  • Constant Vigilance

    Case Study — March 16, 2011
    Centralized planning played a key role in improving productivity during site visits and close monitoring ensured the high standards Quintiles put in place were met.

  • Recruiting Trust

    Case Study — March 16, 2011
    Quintiles enrolls 2 cancer trials, 2 times faster than projected

  • Advancing Prevention in Korea

    Case Study — September 14, 2010
    The original recruitment target and timeline were met with more than 1,100 patients screened to yield 420 randomized patients.

  • Managing Trauma

    Case Study — September 14, 2010
    Quintiles overcame the unpredictability of patient recruitment due to the emergency setup and the client was able to file for approval based on phase II data only.

  • QUINTILES AND KAISER PERMANENTE ANNOUNCE ALLIANCE TO ACCELERATE DRUG DEVELOPMENT

    Press Release — May 18, 2010 - Quintiles is accelerating drug development with the addition of Kaiser Permanente's Southern California Permanente Medical Group to its global site program

  • Regulatory Landscapes for Future Antidiabetic Drug Development

    Hear from the Experts — May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

Page 1 of 3 (26 results)

Subscribe to Email Based on Your Interests

Set preferences